



# PRIORITIZATION TRIAL STRATEGY IN RELAPSED NEUROBLASTOMA

## First relapse

ALK mut/amp	ALK not mutated/not amp
Lorlatinib + TopoCyclo NCT03107988	Follow national guidance or SIOPEX guidelines, when available (ie. TMZ-based chemotherapy + dinutuximab beta/bevacizumab)
Crizotinib + temsirolimus (CRISP) EudraCT 2015-005437-53)	
Brigatinib NCT04925609 Alectinib (only ALK fusion) NCT04774718	Ribociclib-TOTEM NCT05429502

## Subsequent relapses

Molecular target available	Molecular target not available
<b>MYCN amplification</b> Nivo-Entinostat NCT03838042 CYC065-TMZ ESMART NCT02813135	Ribociclib-TOTEM NCT05429502
<b>MDM2 amplification/BCL-2</b> Idasa-Topo-Cyclo/Veneto NCT04029688	Idasa-Topo-Cyclo/Veneto NCT04029688
<b>Cell cycle alterations</b> Ribociclib-TOTEM NCT05429502 Abemaciclib-TMZ NCT04238819 Ribo-everolimus ESMART NCT02813135	Anti-GD2 CAR T Cells* NCT03373097
<b>DNA repair deficiencies</b> Niraparib-dostarlimab NCT04544995 Olaparib NCT04236414 Olaparib-ceralasertib ESMART NCT02813135	Abemaciclib-TMZ NCT04238819
<b>FGFR mut/fusion</b> Erdafitinib NCT04083976 Futibatinib ESMART NCT02813135	METRO-NB2012* NCT02641314
	Niraparib-dostarlimab NCT04544995
	Alocelyvir* Eudra CT: 2019-001154-26
	Ponatinib NCT03934372

## Consolidation strategies

If PR/SD: Naxitamab NCT03363373	If PR/SD: lutetium dotatate (LuDO-N) NCT04903899	If PR/SD: lutetium dotatate (NEUROBLU02)* NCT03966651	If PR/SD: mIBG+nivo+ dinutuximab beta (MiNivAN) NCT02914405
---------------------------------------	--	---	--

### Legend

High priority	Moderate priority	Standard priority
---------------	-------------------	-------------------

\*Open only in one country